Mark Cuban's company will sell brand-name drugs; a $350M biotech venture fund launches from a library whiteboard

Taking stock of the drug industry, from the lab to the medicine chest

April 4, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kris Connor/Getty Images for A+E Networks STAT+ | 'True disruption': Mark Cuban's company will sell brand-name diabetes medicines from J&J Mark Cuban's Cost Plus Drug Company is selling medicines made by Janssen directly to consumers at a greatly reduced price. By Ed Silverman STAT+ | From a public library whiteboard, a $350 million biotech venture fund Cure Ventures, which launched with $350 million for its first fund, plans to invest seed money in around 20 new companies. By Allison DeAngelis STAT+ | The Q2 health tech tracker: 13 key industry events and milestones to watch STAT has your guide to the must-watch regulatory decisions, clinical trial readouts, and conferences in health tech this quarter. By Lizzy Lawrence Photo illustration: Casey Shenery for STAT When confronted with mysterious illness in college, 'Chronically Catherine' started writing To help cope with an array of autoimmune symptoms, Catherine Ames writes a column, "Chronically Catherine," for her college paper. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser